|Bid||132.34 x 300|
|Ask||132.40 x 100|
|Day's Range||132.22 - 133.85|
|52 Week Range||96.06 - 135.18|
|PE Ratio (TTM)||49.67|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone.
Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress. The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint. Altogether, lots of uncertainty whether these data could support a robust commercial adoption.